Go Pro
→ They didn't warn anyone in 1971. This time someone is warning you. (From Reagan Gold Group) (Ad)tc pixel Free JSPRW Stock Alerts

Jasper Therapeutics (JSPRW) Competitors

Jasper Therapeutics logo
$0.01 0.00 (-6.38%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

JSPRW vs. ALVOW, APLMW, ARAV, BIAFW, and BIVIW

Should you buy Jasper Therapeutics stock or one of its competitors? Jasper Therapeutics's main competitors and comparable companies include Alvotech (ALVOW), Apollomics (APLMW), Aravive (ARAV), bioAffinity Technologies (BIAFW), and BioVie (BIVIW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Jasper Therapeutics compare to Alvotech?

Jasper Therapeutics (NASDAQ:JSPRW) and Alvotech (NASDAQ:ALVOW) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Company Net Margins Return on Equity Return on Assets
Jasper TherapeuticsN/A N/A N/A
Alvotech N/A N/A N/A

In the previous week, Jasper Therapeutics and Jasper Therapeutics both had 2 articles in the media. Jasper Therapeutics' average media sentiment score of 0.94 beat Alvotech's score of 0.93 indicating that Jasper Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jasper Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alvotech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jasper TherapeuticsN/AN/AN/AN/AN/A
Alvotech$559.42MN/AN/AN/AN/A

Summary

Jasper Therapeutics and Alvotech tied by winning 1 of the 2 factors compared between the two stocks.

How does Jasper Therapeutics compare to Apollomics?

Apollomics (NASDAQ:APLMW) and Jasper Therapeutics (NASDAQ:JSPRW) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

In the previous week, Apollomics had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for Apollomics and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.94 beat Apollomics' score of 0.29 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Apollomics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Jasper Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Net Margins Return on Equity Return on Assets
ApollomicsN/A N/A N/A
Jasper Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Apollomics$8.50MN/AN/AN/AN/A
Jasper TherapeuticsN/AN/AN/AN/AN/A

Summary

Apollomics beats Jasper Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Jasper Therapeutics compare to Aravive?

Aravive (NASDAQ:ARAV) and Jasper Therapeutics (NASDAQ:JSPRW) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, valuation, analyst recommendations, institutional ownership, earnings and risk.

Company Net Margins Return on Equity Return on Assets
AraviveN/A N/A N/A
Jasper Therapeutics N/A N/A N/A

35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Jasper Therapeutics has lower revenue, but higher earnings than Aravive.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aravive$6.99M0.42-$66.21M-$0.90N/A
Jasper TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Jasper Therapeutics had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Jasper Therapeutics and 0 mentions for Aravive. Jasper Therapeutics' average media sentiment score of 0.94 beat Aravive's score of 0.00 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Aravive Neutral
Jasper Therapeutics Positive

Summary

Aravive beats Jasper Therapeutics on 3 of the 5 factors compared between the two stocks.

How does Jasper Therapeutics compare to bioAffinity Technologies?

bioAffinity Technologies (NASDAQ:BIAFW) and Jasper Therapeutics (NASDAQ:JSPRW) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

In the previous week, bioAffinity Technologies had 1 more articles in the media than Jasper Therapeutics. MarketBeat recorded 3 mentions for bioAffinity Technologies and 2 mentions for Jasper Therapeutics. Jasper Therapeutics' average media sentiment score of 0.94 beat bioAffinity Technologies' score of 0.73 indicating that Jasper Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
bioAffinity Technologies
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Jasper Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Net Margins Return on Equity Return on Assets
bioAffinity TechnologiesN/A N/A N/A
Jasper Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
bioAffinity Technologies$5.85MN/AN/AN/AN/A
Jasper TherapeuticsN/AN/AN/AN/AN/A

Summary

bioAffinity Technologies beats Jasper Therapeutics on 2 of the 3 factors compared between the two stocks.

How does Jasper Therapeutics compare to BioVie?

BioVie (NASDAQ:BIVIW) and Jasper Therapeutics (NASDAQ:JSPRW) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioVieN/AN/AN/AN/AN/A
Jasper TherapeuticsN/AN/AN/AN/AN/A

In the previous week, BioVie and BioVie both had 2 articles in the media. BioVie's average media sentiment score of 1.23 beat Jasper Therapeutics' score of 0.94 indicating that BioVie is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
BioVie
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Jasper Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company Net Margins Return on Equity Return on Assets
BioVieN/A N/A N/A
Jasper Therapeutics N/A N/A N/A

Summary

BioVie beats Jasper Therapeutics on 1 of the 1 factors compared between the two stocks.

Get Jasper Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for JSPRW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JSPRW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JSPRW vs. The Competition

Export
MetricJasper TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$3.71B$6.97B$13.04B
Dividend YieldN/A3.76%2.58%10.72%
P/E RatioN/A10.68269.8625.30
Price / SalesN/A1,305.14601.47101.06
Price / CashN/A103.0170.5350.75
Price / BookN/A17.4913.086.33
Net IncomeN/A-$13.32M$3.45B$347.70M
7 Day PerformanceN/A1.74%1.12%1.07%
1 Month PerformanceN/A1.60%1.79%1.03%
1 Year PerformanceN/A56.43%67.69%20.77%

Jasper Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
JSPRW
Jasper Therapeutics
N/A$0.01
-2.1%		N/A-84.8%$0.00N/AN/A20
ALVOW
Alvotech
N/A$0.15
flat		N/A-87.2%$0.00$559.42MN/A4
APLMW
Apollomics
N/A$0.01
-22.5%		N/A-30.7%$0.00$8.50MN/A59
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
BIAFW
bioAffinity Technologies
N/A$0.05
-26.3%		N/A-26.6%$0.00$5.61MN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:JSPRW) was last updated on 8/14/2026 by MarketBeat.com Staff.
From Our Partners
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Leading AI Insider Issues Urgent Market Warning
A leading AI pioneer has spent $17 million on AI research and tools since 2022, building a platform now used b...
TradeSmith | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump’s New Currency Reset
Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 i...
Porter & Company | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Wall Street is staring at the wrong AI trade
Anthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...
The Oxford Club | Sponsoredtc pixel
Huge AI Announcement Coming on September 3
A $51 billion backlog, a SpaceX partnership, and a presidential endorsement are fueling renewed attention on t...
InvestorPlace | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel